Thrombolytic Therapy Monitoring and Complications
Key Takeaways
- Alteplase is dosed 0.9 mg/kg (maximum 90 mg) with 10 percent as a 1-minute bolus and the remainder infused over 60 minutes within the 4.5-hour window.
- Tenecteplase 0.25 mg/kg (maximum 25 mg) as a single 5-10 second IV bolus is an endorsed alternative requiring no infusion pump.
- Blood pressure must be below 185/110 mm Hg before thrombolysis and kept below 180/105 mm Hg for 24 hours afterward.
- Post-thrombolytic neuro checks and blood pressure run every 15 minutes for 2 hours, then every 30 minutes for 6 hours, then hourly to 24 hours.
- Symptomatic intracranial hemorrhage and orolingual angioedema are the feared complications; both require stopping any infusing drug and immediate escalation.
Agents, doses, and windows
Intravenous thrombolysis is time-sensitive but never a shortcut around safety screening. The 2026 AHA/ASA guideline endorses alteplase or tenecteplase for eligible patients within the 4.5-hour window, with advanced-imaging selection extending some patients to roughly 9 hours or to unknown-onset/wake-up stroke.
- Alteplase (tPA): 0.9 mg/kg, maximum 90 mg. Give 10 percent of the total as an IV bolus over 1 minute, then infuse the remaining 90 percent over 60 minutes. Weight-based dosing must be verified independently — a dosing error is a sentinel-event risk.
- Tenecteplase (TNK): 0.25 mg/kg, maximum 25 mg, as a single IV bolus over 5-10 seconds. No infusion pump is needed, which speeds workflow and simplifies transfer; it is increasingly the preferred agent, especially before thrombectomy.
The nurse's contribution is decisive: confirm LKW, dosing weight, glucose, baseline NIHSS, vital signs, medication and anticoagulant history with last dose, allergies, recent surgery/trauma/bleeding, pregnancy status when relevant, IV access, and consent or surrogate per policy — all running in parallel with imaging and the provider's decision.
Inclusion and exclusion screening
The provider makes the final call, but SCRN candidates must recognize the red flags. General inclusion: a disabling ischemic stroke with measurable deficit, age 18 or older, and treatment startable within the window.
| Major exclusion / caution | Why it matters |
|---|---|
| Intracranial hemorrhage on imaging | Absolute contraindication — lysis worsens bleeding |
| BP that cannot be lowered below 185/110 | Hemorrhage risk; must be controlled before treating |
| Active internal bleeding | Systemic hemorrhage risk |
| Recent intracranial/spinal surgery, serious head trauma, or prior ICH | High bleeding risk |
| Platelets below protocol (e.g. <100,000) or INR > 1.7 | Coagulopathy raises bleeding risk |
| Therapeutic LMWH within 24 h, or DOAC within 48 h (normal renal function) | Active anticoagulation |
| Blood glucose < 50 mg/dL with deficit that resolves on correction | Stroke mimic |
Rapidly improving or non-disabling deficits require careful risk-benefit review, not casual dismissal. Several historically "absolute" exclusions have softened with evidence — for example, minor early ischemic changes on CT, advanced age alone, recent menstruation, and many minor recent procedures no longer automatically bar treatment — so the nurse presents the data and lets the stroke specialist weigh it rather than pre-judging eligibility at the bedside.
Blood pressure thresholds around thrombolysis
Blood pressure governs both eligibility and post-treatment safety. The thresholds are fixed exam facts:
| Phase | Target | Nursing action |
|---|---|---|
| Before thrombolysis | < 185/110 mm Hg | Give ordered labetalol or nicardipine; if BP cannot be controlled, the drug is not given |
| During and after (first 24 h) | < 180/105 mm Hg | Monitor closely; treat excursions per order; avoid overshoot below 140 systolic |
| Non-tPA ischemic patient | Treat only if > 220/120 mm Hg | Permissive hypertension preserves penumbral perfusion |
The 2026 update emphasizes that intensive systolic lowering below 140 mm Hg after thrombolysis or thrombectomy is not beneficial and may cause harm, so the goal is controlled — not aggressive — reduction.
Monitoring schedule after treatment
Once the drug is given, neurologic assessment and blood-pressure monitoring become the nurse's central work, on a standardized schedule: every 15 minutes for the first 2 hours, then every 30 minutes for 6 hours, then hourly through 24 hours. Follow the local order set exactly because these intervals define when complications are caught. Withhold antiplatelet and anticoagulant therapy until the 24-hour follow-up CT is clear and protocol permits. Keep the patient NPO until a swallow screen is passed, avoid unnecessary invasive lines or catheters, and maintain fall and bleeding precautions.
Complications that cannot wait
The most feared complication is symptomatic intracranial hemorrhage (sICH), occurring in roughly 2-7 percent of treated patients. Sudden severe headache, vomiting, acute hypertension, decreased consciousness, new pupillary change, seizure, or any neurologic worsening should trigger immediate escalation and emergent CT. Stop the alteplase infusion while the team evaluates, draw coagulation labs and type-and-screen, and prepare reversal therapy — cryoprecipitate (to replace fibrinogen) with possible tranexamic acid or aminocaproic acid — and airway support.
Orolingual angioedema is the other high-risk event, more common in patients on angiotensin-converting enzyme (ACE) inhibitors. Tongue, lip, or oropharyngeal swelling during or shortly after thrombolysis is an airway emergency: stop the infusion, call for immediate help, support the airway, and prepare antihistamines, corticosteroids, and epinephrine per protocol.
Systemic bleeding may appear as gum bleeding, hematuria, hematemesis, melena, access-site oozing, or expanding ecchymosis. Minor oozing is documented and trended; major bleeding demands urgent notification. On the exam, the safest answer pairs focused assessment with immediate escalation rather than passive observation.
A practical safeguard is avoiding bleeding-prone interventions during and shortly after the infusion: defer noncompressible central lines, arterial punctures, indwelling bladder catheterization, and nasogastric tubes for the early hours unless they are essential, because each creates a bleeding site that lysis can turn dangerous. If a procedure cannot wait, anticipate that the team will weigh the timing against thrombolytic exposure. This caution is a frequent SCRN distractor: an order that is routine on most patients can be exactly the wrong move in the first hours after tPA.
An 80 kg patient is ordered IV alteplase for acute ischemic stroke. How should the nurse expect it to be administered?
A thrombolytic-eligible patient has a blood pressure of 196/112 mm Hg before treatment. What should the nurse anticipate?
Ten minutes into an alteplase infusion, a patient develops tongue swelling and muffled speech. What is the priority action?
Which order should the nurse question during the first 24 hours after thrombolytic therapy unless specifically cleared by protocol?